title: What is the future of bromodomains in targeted drug development?
authors: Nuffield Department of Clinical Medicine, University of Oxford, Target Discovery Institute (TDI), Oxford, UK.
authors: Oleg
authors: O
authors: Fedorov
mesh_terms: D000818:Animals; D002843:Chromatin / Q000378:metabolism*; D055808:Drug Discovery / Q000379:methods*; D051548:Histone Acetyltransferases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods*; D011496:Protein Methyltransferases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D014157:Transcription Factors / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D002843:Chromatin; D014157:Transcription Factors; D011496:Protein Methyltransferases; D051548:Histone Acetyltransferases
keywords: BET inhibitors; bromodomains; cancer; oncogene